| 郭凯波,沈凤飞,黄宏.复方苦参注射液联合放疗治疗恶性肿瘤骨转移的Meta分析[J].浙江中西医结合杂志,2019,29(5): |
| 复方苦参注射液联合放疗治疗恶性肿瘤骨转移的Meta分析 |
| The Efficacy and Safety of Compound Kushen Injection(CKI) Combined with Radiotherapy for Patients with Metastatic Bone Cancer: a meta-analysis |
| 投稿时间：2018-07-01 修订日期：2018-11-19 |
| DOI： |
| 中文关键词: 复方苦参注射液 放疗 恶性肿瘤骨转移 骨痛 Meta分析 |
| 英文关键词:compound Kushen injection radiotherapy metastatic bone cancer Ostealgia Meta-analysis |
| 基金项目: |
|
| 摘要点击次数: 908 |
| 全文下载次数: 1 |
| 中文摘要: |
| [目的]采用Meta分析探究恶性肿瘤骨转移患者应用复方苦参注射液（CKI）联合放疗的疗效及安全性。[方法]通过计算机检索PubMed、EMbase、The Cochrane Library、CNKI、VIP、Wan-Fang以及CBM等数据库，搜集所有CKI联合放疗（试验组）对比单纯放疗（对照组）治疗恶性肿瘤骨转移的随机对照试验（RCT）。[结果]纳入10项RCT研究，共680例患者，其中试验组346例，对照组334例。Meta分析结果显示：试验组在疼痛治疗有效率、疼痛完全缓解率以及骨转移病灶控制率等方面均优于对照组，具有统计学意义（P<0.05）；与对照组相比，试验组能增加1年生存率、改善体力状况，并降低白细胞下降发生率且具有统计学差异（P<0.05）。[结论] CKI联合放疗较单纯化疗在恶性肿瘤骨转移疼痛缓解方面疗效更加显著，且能有效控制骨转移病灶、改善生存预后，并减少白细胞下降等不良反应的发生。因纳入文献的方法学质量评价较低，仍需要大量多中心、大样本、高质量的RCT加以验证。 |
| 英文摘要: |
| [Objective] To assess the efficacy and safety of compound kushen injection (CKI) combined with radiotherapy (RT) for patients with metastatic bone cancer (MBC) by a meta-analysis. [Methods] Databases of PubMed, EMbase, The Cochrane Library, CNKI, VIP, Wan-fang and CBM were retrieved by computer to collect randomized controlled trials (RCTs) on treating MBC patients by CKI combined with RT (experimental group) vs. RT (control group). [Results] Ten RCTs with 680 MBC patients (346 in the experimental group and 334 in the control group) were included. The meta-analysis showed that experimental group was superior to control group in response rate and complete remission rate of ostealgia, as well as the control rate of osseous metastasis, showing significant differences (P<0.05). Moreover, it showed statistically significant differences (P<0.05) that compared with the control group, the experimental group can increase the one-year survival rate, improve the physical condition, and reduce the incidence of leukopenia. [Conclusion] Compared to radiotherapy alone, CKI combined with radiotherapy is more effective in the remission of ostealgia in patients with metastatic bone cancer, and can effectively control osseous metastasis, improve survival prognosis, reduce the occurrence of adverse effects such as leukopenia. However, due to the low methodological quality of included studies, more multi-center, large sample and high-quality RCTs are needed to support. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
